151 related articles for article (PubMed ID: 17297881)
1. [Perspectives for development of polyvalent meningococcal vaccine].
Basnak'ian IA; Aleksakhina NN
Zh Mikrobiol Epidemiol Immunobiol; 2006; (7):54-8. PubMed ID: 17297881
[TBL] [Abstract][Full Text] [Related]
2. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.
Vermont CL; van Dijken HH; van Limpt CJ; de Groot R; van Alphen L; van Den Dobbelsteen GP
Infect Immun; 2002 Feb; 70(2):584-90. PubMed ID: 11796586
[TBL] [Abstract][Full Text] [Related]
3. [Antigenic activity of oral whole-culture meningococcal serogroup B vaccine].
Aleksakhina NN; Basnak'ian IA; Kozlova NN; Verner IK
Zh Mikrobiol Epidemiol Immunobiol; 2004; (4):35-40. PubMed ID: 15481917
[TBL] [Abstract][Full Text] [Related]
4. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
5. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
[TBL] [Abstract][Full Text] [Related]
6. Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera.
Joseph H; Balmer P; Bybel M; Papa T; Ryall R; Borrow R
Clin Diagn Lab Immunol; 2004 Jan; 11(1):1-5. PubMed ID: 14715537
[TBL] [Abstract][Full Text] [Related]
7. [Influence of the growth phase of Neisseria meningitidis on the accumulation of antigens cross-reacting with human antigens in the culture].
Basnak'ian IA; Aleksakhina NN; Iastrebova NE; Vaneeva NP; Kozlova NN
Zh Mikrobiol Epidemiol Immunobiol; 2005; (1):43-9. PubMed ID: 15773399
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
9. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
10. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
11. Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone.
Broderick MP; Romero-Steiner S; Rajam G; Johnson SE; Milton A; Kim E; Choi LJ; Radin JM; Schmidt DS; Carlone GM; Messonnier N; Faix DJ
Clin Vaccine Immunol; 2016 Aug; 23(8):672-80. PubMed ID: 27280619
[TBL] [Abstract][Full Text] [Related]
12. [Level of IgG antibodies to bacteria of 12 species in the blood sera of rabbits, immunized with preparations obtained from Neisseria meningitidis, grown under the stress conditions].
Basnak'ian IA; Aleksakhina NN; Iastrebova NE; Vaneeva NP
Zh Mikrobiol Epidemiol Immunobiol; 2005; (5):14-9. PubMed ID: 16279527
[TBL] [Abstract][Full Text] [Related]
13. [Humoral immune response in animals after the oral administration of group C meningococcal whole-culture preparation].
Aleksakhina NN; Basnak'ian IA; Kozlova NN
Zh Mikrobiol Epidemiol Immunobiol; 2004; (5):71-5. PubMed ID: 15554318
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine.
Katial RK; Brandt BL; Moran EE; Marks S; Agnello V; Zollinger WD
Infect Immun; 2002 Feb; 70(2):702-7. PubMed ID: 11796602
[TBL] [Abstract][Full Text] [Related]
15. Immune responses following meningococcal serogroups A, C, Y and W polysaccharide vaccination in C2-deficient persons: evidence for increased levels of serum bactericidal antibodies.
Brodszki N; Skattum L; Bai X; Findlow H; Borrow R; Jönsson G
Vaccine; 2015 Apr; 33(15):1839-45. PubMed ID: 25707694
[TBL] [Abstract][Full Text] [Related]
16. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
[TBL] [Abstract][Full Text] [Related]
17. Protective potency of recombinant meningococcal IgA1 protease and its structural derivatives upon animal invasion with meningococcal and pneumococcal infections.
Kotelnikova O; Alliluev A; Zinchenko A; Zhigis L; Prokopenko Y; Nokel E; Razgulyaeva O; Zueva V; Tokarskaya M; Yastrebova N; Gordeeva E; Melikhova T; Kaliberda E; Rumsh L
Microbes Infect; 2019; 21(7):336-340. PubMed ID: 30797878
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
19. Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease.
Guttormsen HK; Wetzler LM; Naess A
Infect Immun; 1993 Nov; 61(11):4734-42. PubMed ID: 8406872
[TBL] [Abstract][Full Text] [Related]
20. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children.
Pichichero M; Casey J; Blatter M; Rothstein E; Ryall R; Bybel M; Gilmet G; Papa T
Pediatr Infect Dis J; 2005 Jan; 24(1):57-62. PubMed ID: 15665711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
